VERESCA PRECISION ONCOLOGY
US | Onconostic Technologies, Inc.
EU | 3N Diagnostics Ltd.
®
Genomic Research at the turn of the century established the existence of breast cancer molecular sub-types.
Two decades later, the basal-like sub-type still eludes detection.
The Epithelial Mesenchymal Transition (EMT)
VERESCA FOXC1 IHC
Precision Oncology Test
®
We transformed our complex genomic knowledge base, developed a proprietary monoclonal antibody and manufactured a FOXC1 immunohistochemistry (IHC) test receiving CE Marking for in vitro diagnostic use* to aid in the diagnosis of BLBC and FOXC1 prometastatic cancer cells.
For the first time in over 100 years of diagnosing cancerous tumors, our blockbuster VERESCA FOXC1 IHC theranostic (diagnostic | prognostic | predictive) test provides actionable solutions empowering oncologists with knowledge to guide appropriate therapy abrogating disease progression at the time of initial presentation, as opposed to reactionary therapeutic adjustments years later after unexpected recurrence or distant metastasis symptoms are detected.
FOXC1 SCORE >0 IDENTIFIES THE PROPORTION AND AGGRESSIVE INTENSITY OF FOXC1 PROMETASTATIC CANCER CELL ER+ AND ER- TUMORS
​
FOXC1+ tumors identify individuals who may not benefit from endocrine therapy alone and require additional targeted/chemo therapy
FOXC1 PREDICTS NON-RESPONDERS TO CDK4/6 INHIBITORS/ENDOCRINE THERAPY
FOXC1 > 4 identifies the ER+ BLBC subtype in individuals with ABC and MBC who derive no benefit from ribociclib + fulvestrant treatment.
FOXC1 PREDICTS RESPONDERS TO ENDOCRINE THERAPY + CD4/6i + FGFR1
This is a Paragraph. Click on "Edit Text" or double click on the text box to start editing the content and make sure to add any relevant details or information that you want to share with your visitors.
FOXC1 GUIDES ENDOCRINE THERAPY
​
FOXC1+ tumors identify individuals who may not benefit from endocrine therapy alone and require additional targeted/chemo therapy
FOXC1 PREDICTS NON-RESPONDERS TO CDK4/6 INHIBITORS/ENDOCRINE THERAPY
FOXC1 > 4 identifies the ER+ BLBC subtype in individuals with ABC and MBC who derive no benefit from ribociclib + fulvestrant treatment.
FOXC1 PREDICTS RESPONDERS TO ENDOCRINE THERAPY + CD4/6i + FGFR1
This is a Paragraph. Click on "Edit Text" or double click on the text box to start editing the content and make sure to add any relevant details or information that you want to share with your visitors.